How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

747 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease

The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01054976 Recruitment Status : Completed First Posted : January 22, 2010 Results First Posted : December 24, 2012 Last Update Posted : December 24

2010 Clinical Trials

142. Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease. Full Text available with Trip Pro

Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease. An extended release form of the cholinesterase inhibitor (ChEI) drug galantamine (galantamine-ER) was developed, chiefly to increase adherence to medication regimes in patients with mild-to-moderate Alzheimer's disease (AD). Except for predicted differences in (C(max)) and t(max), comparable doses of once daily galantamine-ER and regular, immediate release galantamine, (galantamine-IR), are pharmacologically equivalent (...) . A 24-week randomized, double-blind, placebo-and active-controlled, multicenter phase III trial, which compared galantamine-IR, galantamine-ER and placebo in subjects with mild to moderate AD (mini-mental state examination [MMSE] score range, 10 to 24) showed that both formulations of galantamine were significantly better than placebo in terms of cognition, although not with regard to global change. There was no difference in drug-related adverse events between galantamine-ER and galantamine-IR

2010 Clinical interventions in aging

143. Galantamine in the Treatment of Minor Depression With Mild to Moderate Alzheimer's Dementia in an Elderly Woman Full Text available with Trip Pro

Galantamine in the Treatment of Minor Depression With Mild to Moderate Alzheimer's Dementia in an Elderly Woman 20944777 2012 08 23 2018 11 13 1555-211X 12 3 2010 Primary care companion to the Journal of clinical psychiatry Prim Care Companion J Clin Psychiatry Galantamine in the treatment of minor depression with mild to moderate Alzheimer's dementia in an elderly woman. 10.4088/PCC.09l00905gry PCC.09l00905 Alagiakrishnan Kannayiram K Department of Medicine, Division of Geriatric Medicine

2010 Primary Care Companion to the Journal of Clinical Psychiatry

144. Effects of galantamine on beta-amyloid release and beta-site cleaving enzyme 1 expression in differentiated human neuroblastoma SH-SY5Y cells. (Abstract)

Effects of galantamine on beta-amyloid release and beta-site cleaving enzyme 1 expression in differentiated human neuroblastoma SH-SY5Y cells. Galantamine (Gal) is an acetylcholinesterase inhibitor and used to treat the symptoms of Alzheimer's disease (AD). Recent studies show that Gal may affect amyloid precursor protein (APP) metabolism and increase release of secretory APPα (sAPPα). However the effect of Gal on amyloid-β peptide (Aβ) release and β-site cleaving enzyme 1 (BACE1) expression

2010 Experimental Gerontology

145. [Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands]. (Abstract)

[Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands]. Since January 2008 in The Netherlands, two cholinesterase inhibitors, oral galantamine and rivastigmine transdermal patch, are registered as a one-day symptomatic treatment for Alzheimer's disease. As no head to head study was performed yet, the objective of this study was to describe the daily practice of oral galantamine and rivastigmine transdermal patch in a real life (...) population of a memory clinic of a suburban teaching hospital in The Netherlands.A randomized open label study in 84 ambulant Alzheimer's patients with at least 6 months follow-up and treated either with oral galantamine (group G) or rivastigmine transdermal patch (group R). Data collection included patients' demographic and disease variables. Adverse events were collected and, in case of interruption of the primary treatment, the alternative treatment was registered.Serious adverse events did not occur

2010 Tijdschrift voor gerontologie en geriatrie Controlled trial quality: uncertain

146. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease. Full Text available with Trip Pro

The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease. A minimum 4-point change at 6 months on the Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) is deemed clinically important, but this cut-point has been little studied in relation to clinical meaningfulness. In an investigator-initiated, clinical trial of galantamine, we investigated the extent to which a 4-point change classifies goal attainment by individual (...) patients.Secondary analysis of the video imaging synthesis of treating Alzheimer's disease (VISTA) study: a 4-month, multi-centre, parallel-group, double-blind, placebo-controlled, trial of galantamine in 130 mild-moderate Alzheimer's disease patients (4-month open-label follow-up). ADAS-cog responses at 6 months were compared with outcomes on three clinical measures: clinician's interview based impression of change-plus caregiver input (CIBIC+), patient/carer-goal attainment scaling (PGAS) and clinician-GAS

2010 International Journal of Geriatric Psychiatry Controlled trial quality: predicted high

148. Speech therapy for treatment of adults with primary progressive aphasia

stimulation on language function in patients with acquired impairments of speech, and a limited number of studies have evaluated these techniques in patients with PPA. Patient Population: Speech therapy has been evaluated in adults with PPA. Clinical Alternatives: There are no approved medical disease-modifying treatments for patients with PPA. Pharmacological interventions are of limited value, and include galantamine, memantine, amphetamine, bromocriptine, and modafinil. Other indirect interventions

2016 Health Technology Assessment (HTA) Database.

149. Obsessive-compulsive disorder

risk of QTc interval prolongation with associated serious ventricular arrhythmia such as torsades de pointes, and sudden death. Aripiprazole, clozapine, darifenacin, galantamine, methadone, metoprolol, pitolisant, procyclidine, ranolazine, risperidone and vortioxetine — paroxetine may increase their plasma concentrations. Atomoxetine, perphenazine, and propafenone — paroxetine may inhibit their metabolism. Asenapine, darunavir, fosphenytoin, phenobarbital, phenytoin, primidone, ritonavir

2018 NICE Clinical Knowledge Summaries

150. Clinical practice guidelines and principles of care for people with dementia

AND MEMANTINE 69 EBR Low Any one of the three acetylcholinesterase inhibitors (donepezil, galantamine or rivastigmine) are recommended as options for managing the symptoms of mild to moderately severe Alzheimer's disease. Any one of the three acetylcholinesterase inhibitors could be considered for managing the symptoms of severe Alzheimer’s disease. 2 Prior to initiation of treatment medical practitioners should consider performing an electrocardiogram (ECG), recording weight and undertaking a falls risk

2016 Clinical Practice Guidelines Portal

151. Antioxidative, antifungal, cytotoxic and antineurodegenerative activity of selected Trametes species from Serbia. Full Text available with Trip Pro

, and that cervix adenocarcinoma cells were the most sensitive to the extracts and commercial cytostatics. T. versicolor mycelium extract was the most effective inhibitor of acetylcholinesterase activity but double weaker than galantamine, and T. gibbosa mycelium extract was significantly better inhibitor of tyrosinase activity than kojic acid for 40.9%. Chemical analysis indicated strong synergistic action of triterpenes, sugars and polyphenols in applied assays. The results suggest that tested Trametes

2018 PLoS ONE

152. Comparison of prescribing practices for older adults treated by female versus male physicians: A retrospective cohort study. Full Text available with Trip Pro

inhibitor (ChEI) drug therapy for dementia management.All community-dwelling Ontario residents aged 66 years and older with dementia and newly dispensed an oral ChEI drug (donepezil, galantamine, or rivastigmine) between April 1, 2010 and June 30, 2016 were included.The association between physician sex and the initiation of a lower than recommended-dose ChEI was examined using generalized linear mixed regression models, adjusting for patient and physician characteristics. Data were stratified

2018 PLoS ONE

156. SNMMI Procedure Standard-EANM Practice Guideline for Amyloid PET Imaging of the Brain

prescribed for dementia patients, such as donepezil, galantamine, and memantine. No drug withdrawal is recommended at this time. 2. Information Pertinent to the Procedure: Several parameters should be taken into consideration in order to improve the quality of the study acquisition and reporting: a) Correlation (preferably using digital image co-registration) with recent or concurrent morphologic imaging studies (e.g. CT, MRI) is recommended to evaluate the amount and location of brain atrophy as well

2016 Society of Nuclear Medicine and Molecular Imaging

159. Management of schizophrenia

of augmentation of antipsychotics with acetylcholinesterase inhibitors identified 13 double blind studies (six with donepezil, three with galantamine and four with rivastigmine,). Significant improvement was found for various aspects of memory (by an average of 28%, in three studies, in 146 participants, 95% CI 0.06 to 0.50, p=0.014) and on the trail making test part A (by 69%, in four studies, in 93 participants, 95% CI -1.14 to -0.23, p=0.003). 125 B Acetylcholinesterase inhibitors may be considered

2013 SIGN

160. Effect of Rivastigmine (Acetyl Cholinesterase Inhibitor) versus Placebo on Manic Episodes in Patients with Bipolar Disorders: Results from a Double Blind, Randomized, Placebo-Controlled Clinical Trial. (Abstract)

Effect of Rivastigmine (Acetyl Cholinesterase Inhibitor) versus Placebo on Manic Episodes in Patients with Bipolar Disorders: Results from a Double Blind, Randomized, Placebo-Controlled Clinical Trial. To treat patients with bipolar disorders (BPD) during the acute phase, the standard procedure is to administer lithium or sodium valproate. To further optimize treatment, acetylcholinesterase inhibitors such as donepezil and galantamine have gained increased interest, though with conflicting

2019 Neuropsychobiology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>